GSK Presents Positive Data For Jideytro In First-Line Ros1-Positive NSCLC
GSK•Positive clinical data for Jideytro
Sept. 14 (Reuters) - GSK plc GSK.L:
- GSK PLC - JIDEYTRO POSITIVE DATA FOR ROS1-POSITIVE NSCLC
- GSK - PRESENTS POSITIVE DATA FOR JIDEYTRO IN FIRST-LINE ROS1-POSITIVE NSCLC
- GSK - JIDEYTRO ACHIEVES 94% OBJECTIVE RESPONSE RATE AT 15.2 MONTHS FOLLOW-UP
- GSK - PLANS US REGULATORY SUBMISSION FOR JIDEYTRO IN 2026
- GSK - 90% OF PATIENTS PROGRESSION FREE AT 12 MONTHS, MEDIAN PFS NOT YET REACHED
- GSK - 70% OF PATIENTS WITH BRAIN METASTASES ACHIEVE COMPLETE CLEARANCE OF DETECTABLE TUMOURS
